Annovis Bio, Inc.
$1.14
$0.04 (+3.64%)
$1.09Day Range$1.16
Key Statistics
Market Cap
$46.95M
Shares Outstanding
42.7M
Primary Exchange
XNYS
Currency
USD
Type
CS
IPO Date
Jan 29, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$1.12
Day High
$1.16
Day Low
$1.09
Volume
682.0K
VWAP
$1.13
Prev Close
$1.10
Transactions
--
Acc. Volume
--
About Annovis Bio, Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
PHARMACEUTICAL PREPARATIONSSIC 28347 employees101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA, 19355484-875-3192IPO Jan 29, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001477845
- Composite FIGI
- BBG00PN9XD40
- Share Class FIGI
- BBG00PN9XDJ4
- Ticker Root
- ANVS
- SIC Code
- 2834
About Annovis Bio, Inc. (ANVS) Stock
Annovis Bio, Inc. (ANVS) closed the 2026-09-18 session at $1.14, up 3.64% versus the previous close (+0.04). The stock opened at $1.12 and traded between $1.09 and $1.16 during that session. Session trading volume was 682K shares. The volume-weighted average price (VWAP) is $1.13.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
Annovis Bio, Inc. has a market capitalization of $46.9 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ANVS is listed on the XNYS exchange. The company employs approximately 7 people. Annovis Bio, Inc. is headquartered in MALVERN, PA. The recorded listing date is 2020-01-29.
On this page you can find market ANVS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.